CSC
ABBV icon

Caldwell Sutter Capital’s AbbVie ABBV Stock Holding History

Caldwell Sutter Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Buy
5,152
+29
+0.6% +$6.24K 0.49% 50
2026
Q1 		$1.11M Sell
5,123
-240
-4% -$53.2K 0.45% 54
2025
Q4 		$1.23M Sell
5,363
-53
-1% -$12.1K 0.52% 47
2025
Q3 		$1.25M Sell
5,416
-619
-10% -$126K 0.54% 44
2025
Q2 		$1.12M Buy
6,035
+72
+1% +$13.4K 0.51% 47
2025
Q1 		$1.25M Sell
5,963
-227
-4% -$44.1K 0.59% 42
2024
Q4 		$1.1M Buy
6,190
+649
+12% +$119K 0.51% 51
2024
Q3 		$1.09M Sell
5,541
-201
-4% -$37.5K 0.51% 50
2024
Q2 		$985K Sell
5,742
-105
-2% -$17.4K 0.49% 53
2024
Q1 		$1.06M Sell
5,847
-344
-6% -$59.3K 0.51% 56
2023
Q4 		$959K Sell
6,191
-114
-2% -$16.6K 0.49% 59
2023
Q3 		$940K Buy
6,305
+38
+0.6% +$5.58K 0.52% 53
2023
Q2 		$844K Buy
6,267
+2,499
+66% +$366K 0.44% 66
2023
Q1 		$601K Buy
3,768
+1,988
+112% +$304K 0.44% 58
2022
Q4 		$288K Buy
+1,780
New +$273K 0.25% 83

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Caldwell Sutter Capital's ABBV Position: Q2 2026 in Review

Caldwell Sutter Capital increased its AbbVie (ABBV) stake by 0.57% in Q2 2026, buying an estimated $6.24K and bringing the position to 5,152 shares worth $1.3M. The position accounts for 0.49% of the portfolio, ranked #50.

Caldwell Sutter Capital first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,225 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Caldwell Sutter Capital held 5,152 shares of AbbVie worth $1.3M as of Q2 2026.
  • Caldwell Sutter Capital bought 29 AbbVie shares in Q2 2026, an estimated $6.24K.
  • AbbVie made up 0.49% of Caldwell Sutter Capital's portfolio in Q2 2026, its #50 holding.
  • Caldwell Sutter Capital first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • 4,225 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Caldwell Sutter Capital's 13F filing for Q2 2026, filed 5 Aug 2026.